EAST SYRACUSE, N.Y. (WSYR-TV) — The Upstate Institute for Global Health is looking for over 1,000 Central New Yorkers to participate in its largest clinical trial, testing a possible vaccine to ...

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive ...

Clostridioides difficile is a notoriously nasty intestinal bug, with few effective treatments and no approved vaccines. But the same technology that enabled the first COVID-19 vaccines has shown early ...

VIENNA, May 5, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal ...

Clostridioides difficile has been traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more ...

A large team of microbiologists, pathologists and infectious diseases specialists affiliated with several institutions in the U.S. has developed an mRNA vaccine that has thus far been found able to ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...